Inhibrx Biosciences, Inc. INBX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s total liabilities & equity?
- Inhibrx Biosciences, Inc. (INBX) reported total liabilities & equity of $183.97M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s total liabilities & equity changed year-over-year?
- Inhibrx Biosciences, Inc.'s total liabilities & equity decreased by 24.2% year-over-year, from $242.64M to $183.97M.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s total liabilities & equity?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s total liabilities & equity has grown at a -31.0% compound annual growth rate (CAGR), from $307.89M to $146.48M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.